Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

HORSHAM, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. announced today that the Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.

"We are pleased by the FDA's acceptance of our Biologics License Application for review of ustekinumab," stated Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "Ustekinumab has yielded promising efficacy and safety results in Phase 3 clinical trials, and we look forward to working closely with the FDA during their ongoing review of this potential new treatment for psoriasis."

Centocor, Inc. announced that it had submitted the BLA for ustekinumab in December 2007 based on its comprehensive development program including data from two large Phase 3 multicenter, randomized, double-blind, placebo- controlled trials involving nearly 2,000 patients that evaluated the safety and efficacy of ustekinumab in the treatment of moderate to severe plaque-type psoriasis. The primary endpoint of both studies was the proportion of patients who achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis Area and Severity Index (PASI 75). Acceptance of the BLA filing does not mean that a license has been issued for this product nor does it represent any evaluation of the adequacy of the data submitted in the BLA. In December 2007 the Marketing Authorization Application (MAA) for ustekinumab was submitted in Europe and is currently under review by the European Medicines Agency (
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... Europe and the United States and plenary talks by ... for SPIE Optics + Optoelectronics next month ... 700 technical presentations in 17 conferences alongside a two-day ... optics and photonics , the event will run 13-16 ...
(Date:3/30/2015)... , March 30, 2015 ... Richmond Pharmacology ist das erste Zentrum ... am Royal Free Hospital in London ... Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten begonnen ... Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen Herz- ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Earlier this ... the promotion of hair regrowth in adult men and ... I-II or Norwood Hamilton classifications of IIa-V and Fitzpatrick ... industry plagued by products that over-promise and under-deliver, FDA ... renewing faith and confidence among more than 80 million ...
Breaking Biology Technology:Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2
... Simcere,Pharmaceutical Group (NYSE: SCR ), a leading manufacturer ... patented,anti-cancer biotech product Endu in China, today announces the ... Marketing and the promotion,of Baoxing Zha and Dasheng Sun ... respectively., The company also announces that Mr. Yat ...
... Germany and OXFORD, England, March 20 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt ... press conference in Frankfurt on the occasion of the,publication of ... will be held in English., Date: Friday, March 28, ... EDT), To join the audio webcast and to access ...
... DIEGO, March 20 Nereus Pharmaceuticals, Inc., a,pioneer ... announced,that enrollment has begun in a Phase 1b ... combination with standard chemotherapy,in patients with non-small cell ... in a Phase 1 single-agent clinical trial assessing ...
Cached Biology Technology:Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions 2Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions 3Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 2Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 3
(Date:3/12/2015)... IriTech, a leading iris based identity management ... Instruments Design Network, announced today that the Chief Minister ... USB MK2120U device during a launching event of Andhra ... The iris scanner is manufactured by U.S. ... India through its Indian partner, Biometronic ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March 17, ... here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost & ... - http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies ... compete in several different markets and industries. This ... witnessing an uptrend. Join Frost ...
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year ... Unexpected, Hammacher Schlemmer introduces The Eye Scanning Password ... before granting access to secure websites or sensitive data. ... verify travelers at international borders, the device has a ... pattern points of the iris, converting them into an ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... of metagenomics, where the DNA of entire communities of ... perhaps since the invention of the microscope -- to ... report from the National Research Council. The report ... advances in the field in the same way that ...
... in an East Tennessee valley adjacent to the Oak ... from weapons manufacturing at the facility between 1951 and ... for miles from the contaminated site. , But ... his FSU oceanography department team will help clean up ...
... of growth hormone to boost athletic performance can lead to ... British Journal of Sports Medicine. , The study reports the ... emergency care for chest pain. , He had lost ... experienced excessive urination, thirst, and appetite. , He admitted ...
Cached Biology News:New science of metagenomics 'will transform modern microbiology' 2New science of metagenomics 'will transform modern microbiology' 3New science of metagenomics 'will transform modern microbiology' 4'Hidden-hero' microbes in soil, water may help naturally clean toxic sites 2
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 ... N O 6 ,M.W.= 408.63 ... Clear (2% in DMF) ,Biological Activity: ... M13 ,Elemental Analysis: Agrees with theoretical ...
Biology Products: